New drug cocktail shows promise for tough head and neck cancers
NCT ID NCT03818061
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, atezolizumab and bevacizumab, in 33 adults with advanced head and neck cancer that had worsened after chemotherapy. The goal was to see if the combo could shrink tumors or slow disease progression. Results may help guide future treatments for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq) and Bevacizumab (Avastin)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced head and neck cancer that has stopped responding to chemotherapy.
What could go wrong
This is a small, early-phase study with only 33 participants, so results may not apply to everyone. The combination may cause side effects like high blood pressure or immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Paul Strauss
Strasbourg, 67065, France
-
Clinique Mutualiste de l'Estuaire
Saint-Nazaire, 44606, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Curie
Paris, 75005, France